bsm-54071R [Primary Antibody]
MAP3K7 (11A1) Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: MAP3K7

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 6885

Swiss Prot: O43318

Source: C terminal Human MAP3K7

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity.

Size: 100ul

Concentration: 1ug/ul

Predicted Molecular Weight: 67


Cross Reactive Species: Human
Mouse

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: Human Placenta; Probed with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:1000 overnight at 4°C followed by a conjugated secondary antibody for 60 minutes at 37°C.


IF(ICC) staining with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.


IF(ICC) staining with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100 in N2A cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.


Paraformaldehyde-fixed and paraffin-embedded Human Prostate tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Mouse Stomach tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Human Placenta tissue incubated with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Flow cytometric analysis of A431 cells with MAP3K7 (11A1) Monoclonal Antibody (bsm-54071R) at 1:100 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).